Early safety check for new drug UCB3101 in healthy volunteers
NCT ID NCT06555601
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was an early, first-in-human trial to see if a single dose of UCB3101 is safe and tolerable in healthy adults aged 18 to 65. Researchers gave either the drug or a placebo and watched for side effects. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UP0124 1
Edegem, Belgium
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates